Stability of placental growth factor, soluble fms-like tyrosine kinase 1, and soluble fms-like tyrosine kinase 1 e15a in human serum and plasma

Placenta. 2019 Oct:86:1-3. doi: 10.1016/j.placenta.2019.08.001. Epub 2019 Aug 7.

Abstract

Placental growth factor (PlGF), total soluble fms-like tyrosine-kinase 1 (sFlt-1) and its placental-specific variant, sFlt-1 e15a, show promise as biomarkers for the prediction and diagnosis of preeclampsia. This study describes the degradation of PlGF, sFlt-1 and sFlt-1 e15a within maternal serum and plasma to assist clinical implementation. Whole blood was refrigerated at 4 °C for up to 48 h prior to centrifugation for isolation of plasma and serum. PlGF and sFlt-1 were quantified using the B.R.A.H.M.S Kryptor Compact PLUS; sFlt-1 e15a via a custom ELISA. All three analytes are stable for at least 48 h at 4 °C. Serum and plasma performed comparably.

Keywords: Anti-angiogenic factors; PlGF; Preeclampsia; sFlt-1; sFlt-1 e15a.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Specimen Collection
  • Female
  • Humans
  • Placenta Growth Factor / blood*
  • Pregnancy
  • Prospective Studies
  • Protein Stability
  • Vascular Endothelial Growth Factor Receptor-1 / blood*

Substances

  • Placenta Growth Factor
  • FLT1 protein, human
  • Vascular Endothelial Growth Factor Receptor-1